58.54
0.44 (0.76%)
Previous Close | 58.10 |
Open | 58.02 |
Volume | 44,406 |
Avg. Volume (3M) | 2,091,910 |
Market Cap | 11,226,931,200 |
Price / Earnings (TTM) | 21.68 |
Price / Earnings (Forward) | 13.76 |
Price / Sales | 3.86 |
Price / Book | 1.92 |
52 Weeks Range | |
Earnings Date | 4 Aug 2025 |
Profit Margin | 17.76% |
Operating Margin (TTM) | 30.05% |
Diluted EPS (TTM) | 2.70 |
Quarterly Revenue Growth (YOY) | 14.80% |
Quarterly Earnings Growth (YOY) | 109.40% |
Total Debt/Equity (MRQ) | 10.39% |
Current Ratio (MRQ) | 5.52 |
Operating Cash Flow (TTM) | 700.26 M |
Levered Free Cash Flow (TTM) | 411.56 M |
Return on Assets (TTM) | 6.38% |
Return on Equity (TTM) | 9.64% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | BioMarin Pharmaceutical Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | -1.0 |
Technical Oscillators | 2.0 |
Average | 0.50 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Mid Growth |
% Held by Insiders | 0.77% |
% Held by Institutions | 98.91% |
Ownership
Name | Date | Shares Held |
---|---|---|
Primecap Management Co/Ca/ | 31 Mar 2025 | 17,773,281 |
Dodge & Cox | 31 Mar 2025 | 14,955,240 |
Viking Global Investors Lp | 31 Mar 2025 | 10,800,059 |
Capital Research Global Investors | 31 Mar 2025 | 9,150,655 |
Ameriprise Financial Inc | 31 Mar 2025 | 4,207,563 |
Norges Bank | 31 Dec 2024 | 3,569,831 |
Elliott Investment Management L.P. | 31 Mar 2025 | 3,500,338 |
Aqr Capital Management Llc | 31 Mar 2025 | 2,925,805 |
Deutsche Bank Ag\ | 31 Mar 2025 | 1,887,353 |
52 Weeks Range | ||
Price Target Range | ||
High | 104.00 (Goldman Sachs, 77.65%) | Buy |
Median | 91.00 (55.44%) | |
Low | 78.00 (Citigroup, 33.24%) | Hold |
Average | 91.00 (55.44%) | |
Total | 1 Buy, 1 Hold | |
Avg. Price @ Call | 62.05 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Goldman Sachs | 05 May 2025 | 104.00 (77.65%) | Buy | 62.06 |
Citigroup | 02 May 2025 | 78.00 (33.24%) | Hold | 62.03 |
No data within this time range.
Date | Type | Details |
---|---|---|
01 Jul 2025 | Announcement | BioMarin Announces Completion of Acquisition of Inozyme |
24 Jun 2025 | Announcement | BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress |
16 May 2025 | Announcement | BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma |
12 May 2025 | Announcement | BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings |
01 May 2025 | Announcement | BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance |
17 Apr 2025 | Announcement | BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |